Clinical effect of ligustrazine through ultrasonic conductometric prostate therapeutic apparatus on type III prostatitis and its influence on inflammatory factors

Abstract

Objective To explore the ligustrazine through ultrasonic conductometric prostate therapeutic apparatus in the application of type Ⅲ prostatitis patients and this kind of treatment effects on inflammatory factors in patients with prostatic fluid. Methods From August 2016 to April 2018, 90 patients with type Ⅲ prostatitis who were hospitalized in our hospital were randomly divided into the ligustrazine group and the normal group, two groups of patients were treated with the same method, the ligustrazine group received ultrasonic conductometric ligustrazine, and the normal group received ultrasonic conductometric normal saline, both by rectum. The NIH-CPSI index, the levels of IL-1β, IL-8, TNF-α, PGE2 and the treatment effect of two groups after 1 month were compared. Results After 1 month of treatment, the NIH-CPSI index and inflammatory factors in the two groups were lower than those before the intervention (P<0.05). The NIH-CPSI index and inflammatory factors in the intervention group were lower than those in the control group (P<0.05). After 1 month of treatment, the treatment effect of the intervention group was better than that of the control group (P<0.05). Conclusions Ligustrazine through ultrasonic conductometric prostate therapeutic apparatus has a good effect on type Ⅲ prostatitis patients, the drug action is safe and stable, greatly promotes the recovery of patients. Key words: Prostatitis; Alkaloids; Ultrasonic Therapy; Chemokines